Skip to main content

EASD 2024

EASD 2024

9–13 September | Madrid

The 60th European Association for the Study of Diabetes Annual Meeting delivers research developments, current treatments, technologies, and care related to type 1 and type 2 diabetes and their complications. We bring you the latest news from the meeting.

Semaglutide reduces obesity-related MACE risk despite kidney impairment

SELECT trial shows semaglutide reduces the risk for major adverse cardiovascular events in people with overweight or obesity regardless of kidney function impairment.

Read more

Diabetes & Endocrinology Update

Covering the latest advances and keeping your practice up to date. Receive newsletters personally curated for the busy diabetes & endocrinology specialist.

Initial FAERS analysis indicates ‘reassuring’ adverse event profile for tirzepatide

A real-world study of tirzepatide use in the USA suggests the agent has a similar gastrointestinal adverse event profile to that of GLP-1 receptor agonists.

Liraglutide reduces BMI for young children with obesity

Liraglutide is more effective at reducing BMI than placebo in children with obesity younger than 12 years old.

Diabetes-related microvascular complications linked to increased gum disease risk

Diabetic neuropathy and retinopathy are associated with an increased risk for moderate or severe periodontitis in people with type 2 diabetes.

SGLT2 inhibitors new treatment option for children with type 2 diabetes?

Canagliflozin shown to lower HbA1c in children with type 2 diabetes and have a similar safety profile to that in adults.

Weekly insulin efsitora alfa 'noninferior' to daily degludec in type 2 diabetes

Once weekly insulin efsitora alfa reduces HbA1c by a similar amount to daily insulin degludec in people with type 2 diabetes, results of the QWINT-2 trial show.

Read more

Semaglutide and tirzepatide effective in type 1 diabetes

Semaglutide and tirzepatide improve glycemic control and weight loss in people with type 1 diabetes. 

AI algorithm accurately screens for type 2 diabetes

A speech-based AI algorithm correctly predicts type 2 diabetes in patients. 

Direct comparison tirzepatide, liraglutide and semaglutide in network meta-analysis

Tirzepatide may be superior to liraglutide and semaglutide for weight loss in obese patients, but with a greater number of gastrointestinal side effects. 

Higher time in tight range, fewer complications

The higher the percentage of blood glucose values within a “tight limit range”, the lower the number of diabetes complications.

‘Noninferior’ reduction of type 1 diabetes HbA1c by weekly insulin efsitora alfa

Weekly treatment with insulin efsitora is noninferior to daily insulin degludec for the reduction of HbA1c in adults with type 1 diabetes, show the findings of the QWINT-5 trial.

Read more

Finerenone: cardiorenal benefits for broad patient population

Pooled analysis of three studies with finerenone suggests cardiorenal benefits for patients at high risk for cardiovascular, renal, and metabolic disease.

First renal outcome study with semaglutide in very-high-risk group

Semaglutide significantly reduces the risk of progression of kidney disease by 24% versus placebo in adults with type 2 diabetes and chronic kidney disease.

Effect of diabetes medication on neuropsychiatric disorders

SGLT2 inhibitors appear to provide better protection for neuropsychiatric health than GLP1 receptor agonists and metformin in patients with type 2 diabetes.

Insulin resistance related to 31 diseases

Data analysis finds that insulin resistance is linked to 31 diseases, including sleeps disorders, bacterial infections and pancreatitis.

Tirzepatide significantly reduces UACR in individuals with obesity and type 2 diabetes

Tirzepatide reduces UACR without adversely affecting eGFR in people with obesity and type 2 diabetes, shows post-hoc analysis of SURMOUNT-2.

Weight loss with new obesity drug amycretin

Amycretin was safe and reliable in people with obesity but without diabetes, with the highest dose leading to over 13% reduction in bodyweight in 12 weeks.

Stay up to date with more from Springer Medicine

Episode 10: Disease-modifying therapy for type 1 diabetes

Prof. Chantal Mathieu explains the progress being made with disease-modifying therapy for type 1 diabetes and how it has the potential to transform the current treatment landscape. 

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.

Keynote webinar | Spotlight on diet and diabetes

  • Webinar | 08-11-2023 | 18:00 (CET)

Recent EASD dietary guidelines underpin this discussion on weight management, including use of therapeutic diets, food types and processing, plus psychological factors that influence patient success, and the drivers of healthy eating and diabetes control.

CME & eLearning

Real-world application of CGM technology in primary care (Link opens in a new window)

1.0 AMA PRA Category 1 Credit(s)

Refine the application of CGM technology in primary care to enhance the management of type 2 diabetes. Benefit from key updates and experiential learning using CGM devices, and practice your clinical decision-making skills.

Supported by:
  • Abbott

Techniques for implementing continuous glucose monitoring in primary care (Link opens in a new window)

  • Diabetes
  • Independent Medical Education

1.5 AMA PRA Category 1 Credit(s)

Stay up to date with the rapidly changing CGM landscape with this program of tweetorials, vodcasts and infographics. Learn how to implement and integrate CGM into diabetes management to improve patient care and outcomes.

Supported by:
  • Abbott

T2D & CKD: putting evidence into practice (Link opens in a new window)

Vodcasts providing expert guidance on the multidisciplinary approach to chronic kidney disease in patients with type 2 diabetes, plus patient scenarios to assist your decision-making and put the latest clinical guidelines into context.

This program is not available to users in the UK and US.

Supported by:
  • Novo Nordisk A/S